Roche Wins Ruling On Mircera Importation; Court to Hear Injunction Appeal

Although it may not make much difference for its follow-on biologic Mircera (epoetin beta), Roche has won a battle with Amgen that could affirm a layer of intellectual property protection for all follow-on biologics in the U.S